Jason J Schafer
Overview
Explore the profile of Jason J Schafer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
593
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prioli K, Akincigil A, Namvar T, Mitchell-Williams J, Schafer J, Cunningham R, et al.
J Manag Care Spec Pharm
. 2023 Jul;
29(8):970-980.
PMID: 37523315
The mortality, morbidity, health care utilization, and cost attributable to vaccine-preventable diseases are substantial for those aged 50 years and older. Although vaccination is the most cost-effective strategy to prevent...
2.
Schafer J, Zimmerman M, Walshe C, Cerankowski J, Shimada A, Keith S
Obesity (Silver Spring)
. 2022 Jun;
30(6):1197-1204.
PMID: 35674696
Objective: Switching from tenofovir disoproxil fumarate (TDF)- to tenofovir alafenamide (TAF)-containing antiretroviral therapy may negatively influence weight, cholesterol, and atherosclerotic cardiovascular disease risk. The extent of these changes and their...
3.
Emmons R, Hastain N, Miano T, Schafer J
J Pharm Pract
. 2021 Mar;
35(4):568-572.
PMID: 33678059
Background: Recent studies suggest that statins are underprescribed in patients living with HIV (PLWH) at risk for atherosclerotic cardiovascular disease (ASCVD), but none have assessed if eligible patients receive the...
4.
Schafer J, Pandit N, Cha A, Huesgen E, Badowski M, Sherman E, et al.
Open Forum Infect Dis
. 2021 Jan;
8(1):ofaa625.
PMID: 33511239
Background: Switching antiretroviral therapy (ART) in people with HIV (PWH) can influence their risk for drug-drug interactions (DDIs). The purpose of this study was to assess changes in the incidence...
5.
Schafer J, Sassa K, OConnor J, Shimada A, Keith S, DeSimone J
Open Forum Infect Dis
. 2019 Oct;
6(10):ofz414.
PMID: 31660372
Background: Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) can improve renal function and bone mineral density in people with human immunodeficiency virus (PWH). The...
6.
Hastain N, Santana A, Schafer J
Ann Pharmacother
. 2019 Aug;
54(1):36-42.
PMID: 31364373
Current guidelines advocate for antiretroviral therapy (ART) simplification in patients on complicated regimens. Simplifying ART improves patient adherence and quality of life, but changes in drug interactions (DIs) are uncertain....
7.
Schafer J, McRae J, Prioli K, Harris L, McCoy M, Cannon-Dang E, et al.
Ethn Health
. 2018 Sep;
26(3):364-378.
PMID: 30175602
To assess the association of the Pharmacists' Pneumonia Prevention Program (PPPP) with changes in beliefs related to pneumonia vaccination (PV) in a predominately older African American population. PPPP was an...
8.
Pizzi L, Prioli K, Harris L, Cannon-Dang E, Marthol-Clark M, Alcusky M, et al.
Ann Pharmacother
. 2017 Nov;
52(5):446-453.
PMID: 29172664
Background: Vaccination is the best way to prevent pneumococcal disease (PD), but 40% of older adults remain unvaccinated nationwide, with even greater nonvaccination rates among African Americans (AAs). Prior studies...
9.
Gibson A, Shah B, Nambiar P, Schafer J
Ann Pharmacother
. 2016 Jul;
50(11):942-952.
PMID: 27465879
Objective: To review the pharmacology, efficacy, safety, and place in therapy for tenofovir alafenamide (TAF). Data Sources: A search using PubMed was conducted (2004 to May 2016) using the following...
10.
Schafer J, Gill T, Sherman E, McNicholl I
Am J Health Syst Pharm
. 2016 Feb;
73(7):468-94.
PMID: 26892679
No abstract available.